Agustin Iskandar
Departemen Patologi Klinik Dan Kedokteran Laboratorium, Fakultas Kedokteran, Universitas Brawijaya / RSUD Dr Saiful Anwar, Malang

Published : 30 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Jurnal Respirologi Indonesia

The Differences in Urokinase Plasminogen Activator System in Lung Cancer Patients Before and After Chemotherapy Tri Wahju Astuti; Agustin Iskandar; Mufidatun Hasanah; Lindayanti Sumali; Dian Nugrahenny
Jurnal Respirologi Indonesia Vol 41, No 4 (2021)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v41i4.214

Abstract

Background: Lung cancer is still the leading cause of death for malignancies worldwide. Urokinase plasminogen activator (uPA), its soluble receptor (suPAR), and its inhibitor (PAI-1) play an important role in tumor invasion and metastasis. This study aimed to evaluate the differences in the urokinase plasminogen activator system (uPA, suPAR, and PAI-1) in lung cancer patients before and after chemotherapy.Methods: This research was an observational analytical study with a cross-sectional design. The subjects were 30, consisting of 17 lung cancer patients before chemotherapy and 13 lung cancer patients after chemotherapy for 4 or 6 cycles. The levels of serum uPA, suPAR, and PAI-1 were measured by enzyme-linked immunosorbent assay (ELISA). Results: In lung cancer patients before chemotherapy, there were no significant (p>0.05) differences in levels of serum uPA, suPAR, and PAI-1 between patients with stage III and IV. The highest serum uPA and suPAR levels were found in adenocarcinoma cell types and the highest serum PAI-1 level in adenoepidermoid cell types. After chemotherapy, serum suPAR and PAI-1 were significantly (p < 0.05) decreased in lung cancer patients. However, there were no significant (p>0.05) differences in the levels of serum uPA, suPAR, and PAI-1 between patients with chemotherapy responses for stable and progressive diseases. Conclusion: This study revealed that suPAR and PAI-1 levels were decreased in lung cancer patients who had received chemotherapy. This can occur due to decreased tumor cells activity. 
Co-Authors Aditya Sri Listyoko Agustina Tri Endharti Aina Angelina Akmaly, Triyana Dian Dhuha Alim, Fathi Nabila Amalia, Najwa Anik Widijanti Aprilia, Andrea Aris Widayati Aryati Aryati Aryati Aryati Aryati Aryati Beti Ernawati Dewi Carla Pramudita Susanto Catur Suci Sutrisnani Corebima, Brigitta IRV Deasy Ayuningtyas Tandio Dewi, Rose Khasana Dian Nugrahenny Dina Fauziah Edi Widjajanto Eko Sulistijono Eko Sulistijono Ery Olivianto Fran Siska Hambiah Hari Oki Hambiah Hari Oki Hamid, Aulia A. Hardi Darmawan Hartanti, Khoirunisah Dwi Herdiman T. Pohan Ihda Dian Kusuma Indriana, Kristin Jahono, Maxie Felix Joko Agus Gunawan Karima, Karima Kautsarani, Intan Khadafi Indrawan Kristin Indriana Leonard Nainggolan Lindayanti Sumali Loeki Enggar Fitri Ludytajati, Ferine Maisaroh, Luluk Mayashita, Dearikha Karina Mirza, Sarah Zoraya Mufidatun Hasanah Muhammad Anshory Muhammad Anshory, Muhammad Mulyohadi Ali Mustika Dewi Nada Putri Pranidya Norwahyuni, Yuyun Novi Khila Firani Novi Kurnianingsih Nur Permatasari Nur Samsu Prameswari, Asri Pranidya, Nada Putri Pratama, Gusti Rajendra Yoga Putri Wulan Akbar Rahajuningsih Dharma Rambe, Annisa Fadhila Aurelia Rianto Setiabudy Riskawati, Yhusi Karina Rosari, M Angelina de Sanjaya, Hayyu Rafina Saptadi Yuliarto Seskoati Prayitnaningsih Settrin Chenderawasi Siska, Fran Sudjari Sudjari Suhendro Suhendro Syahfitri, Rininta Syahrul Chilmi Tri Wahju Astuti, Tri Wahju Triwahju Astuti Wafi, Muhammad Wihastuti TA Yeni Ayu Prihastuti Yeni Ayu Prihastuti Yuanita Mulyastuti Yuniasih, Kristina